Biography and Research Information
OverviewAI-generated summary
Catherine Ma's research focuses on understanding and predicting the progression of plasma cell disorders, particularly Monoclonal Gammopathy of Undetermined Significance (MGUS) to multiple myeloma. Her work investigates molecular signatures and risk factors associated with disease progression, with a specific emphasis on health disparities. Ma has published research on the Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting MGUS progression. She has also identified risk factors for myeloma progression in African American patients and examined the Low-Bone (LB) subtype of multiple myeloma in this population, noting its inferior outcomes and resistance to progression in certain contexts.
Ma is a Co-Principal Investigator on a significant grant from the NIH/National Institute on Minority Health and Health Disparities, totaling $4,749,323. This funding supports research within the Center for Research, Health and Society, underscoring a commitment to addressing health disparities. Her collaborations at the University of Arkansas for Medical Sciences include extensive work with Guido Tricot, David E. Mery, and Hongwei Xu, as evidenced by multiple shared publications.
Metrics
- h-index: 1
- Publications: 6
- Citations: 2
Selected Publications
-
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025)
-
Identification of Risk Factors for Myeloma Progression in African American Patients (2024)
-
The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans (2024)
-
Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression (2024)
Federal Grants 1 $4,749,323 total
NIH/National Institute on Minority Health and Health Disparities
Co-PI
Sep 2021 - Jun 2026
Collaboration Network
Top Collaborators
Clyde Bailey
Winthrop Rockefeller Foundation
4 shared publications
In database
- Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma
- Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression
- The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
- Identification of Risk Factors for Myeloma Progression in African American Patients
Samer Al Hadidi
Winthrop Rockefeller Foundation
4 shared publications
In database
- Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma
- Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression
- The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
- Identification of Risk Factors for Myeloma Progression in African American Patients
Carolina Schinke
University of Arkansas for Medical Sciences
4 shared publications
In database
- Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma
- Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression
- The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
- Identification of Risk Factors for Myeloma Progression in African American Patients
Maurizio Zangari
Winthrop Rockefeller Foundation
4 shared publications
In database
- Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma
- Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression
- The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
- Identification of Risk Factors for Myeloma Progression in African American Patients
Sharmilan Thanendrarajan
Winthrop Rockefeller Foundation
4 shared publications
In database
- Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma
- Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression
- The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
- Identification of Risk Factors for Myeloma Progression in African American Patients
John D. Shaughnessy
University of Arkansas for Medical Sciences
4 shared publications
In database
- Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma
- Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression
- The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
- Identification of Risk Factors for Myeloma Progression in African American Patients
Hongwei Xu
Winthrop Rockefeller Foundation
3 shared publications
In database
- Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression
- The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
- Identification of Risk Factors for Myeloma Progression in African American Patients
Frits van Rhee
Winthrop Rockefeller Foundation
3 shared publications
In database
- Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression
- The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
- Identification of Risk Factors for Myeloma Progression in African American Patients
David E. Mery
Winthrop Rockefeller Foundation
3 shared publications
In database
- Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma
- The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
- Identification of Risk Factors for Myeloma Progression in African American Patients
Guido Tricot
University of Arkansas for Medical Sciences (US)
3 shared publications
- Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma
- The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
- Identification of Risk Factors for Myeloma Progression in African American Patients
Fumou Sun
Winthrop Rockefeller Foundation
2 shared publications
In database
- Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma
- Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression
Fenghuang Zhan
University of Arkansas for Medical Sciences (US)
2 shared publications
- Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression
- Identification of Risk Factors for Myeloma Progression in African American Patients
Yihao Zhan
Central South University (CN)
2 shared publications
- The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
- Identification of Risk Factors for Myeloma Progression in African American Patients
Hongling Peng
Central South University (CN)
2 shared publications
- The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
- Identification of Risk Factors for Myeloma Progression in African American Patients
Eric R. Siegel
University of Arkansas for Medical Sciences
2 shared publications
In database
- The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
- Identification of Risk Factors for Myeloma Progression in African American Patients
Similar Researchers
Based on overlapping research topics
Sharmilan Thanendrarajan
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Health disparities and outcomes
Monoclonal and Polyclonal Antibodies Research
Fenghuang Zhan
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
Disease Mechanisms Research
Daisy Alapat
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Health disparities and outcomes
Cancer-related molecular mechanisms research
Bart Barlogie
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
Disease Mechanisms Research
Philip Farmer
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
Disease Mechanisms Research
Corey O. Montgomery
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
Disease Mechanisms Research